Wirksamkeit von Tocilizumab bei der Therapie der rheumatoiden Arthritis: Besserung der klinischen Symptome: Literaturverzeichnis

  1. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19: 12–19.

  2. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised, controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–1167.

  3. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010; 69:88–96.

  4. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: Tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–2980. www.ncbi.nlm.nih.gov/pubmed/18821691

  5. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–997.

  6. Kremer JL, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: The LITHE study. Arthritis Rheum 2011; 63 (3): 609–621

  7. Yamanaka H, Tanaka Y, Inoue E, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: Results from a retrospective study (REACTION study). Mod Rheumatol. 2011 Apr;21(2):122-33. Abstract www.ncbi.nlm.nih.gov/pubmed/20953815

  8. Hirabayashi Y, Ishii T, Harigae H. Clinical efficacy of Tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol Int. 2010;30:1041–1048 Abstract http://www.ncbi.nlm.nih.gov/pubmed/19701637

  9. Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Syuji Takei, Yoshiya Tanaka, Kyoko Ito, Hisashi Yamanaka: Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients Ann Rheum Dis 2011;70:2148-2151
    http://ard.bmj.com/content/70/12/2148.full

  10. Gerd R Burmester, E Feist, H Kellner, J Braun, C Iking-Konert, A Rubbert-Roth: Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA), Ann Rheum Dis doi:10.1136/ard.2010.139725 Published Online First 27 December 2010
     Full Text 

  11. EULAR 2011 - FRI0365 COMPARISON OF TOCILIZUMAB AS MONOTHERAPY OR WITH ADD-ON DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO PREVIOUS TREATMENTS: ACT-SURE RESULTS. J. Sibilia 1,*, W. Graninger 2, A. Östör 3, J. A. Román Ivorra 4, J. Wollenhaupt 5, A. Stancati 6, C. Bernasconi 6, V. Bykerk 7 and ACT-SURE Study Group. Abstract, https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=58163

  12. EULAR 2011- SAT0306: Tocilizumab Treatment in Patients with Rheumatoid Arthritis and Inadequate Response to DMARDs and/or TNF Inhibitors: ACT-SURE Final Results. Vivian P. Bykerk, Jose Álvaro-Gracia, Jose Andres Román Ivorra, Michael T. Nurmohamed, Karel Pavelka, Corrado Bernasconi, Andrea Stancati, Jean Sibilia, Andrew Östör on behalf of ACT-SURE Study Group

  13. EULAR 2011 -OP0020 TOCILIZUMAB (TCZ) PLUS METHOTREXATE (MTX) DOES NOT HAVE SUPERIOR CLINICAL EFFICACY TO TCZ ALONE IN RA PATIENTS WITH INADEQUATE RESPONSE TO MTX: 24-WEEK RESULTS OF THE ACT-RAY STUDY M. Dougados, T. Huizinga, T. Sheeran, P. Tak, P. Conaghan, F. Navarro-Sarabia, A. Hou , C. Bernasconi , K. Kissel
    Abstract
    https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=58181

  14. A. M. van Gestel, M. L. L. Prevoo, M. A. van't Hof, M. H. van Rijswijk, L. B. A. van de Putte, P. L. C. M. van Riel: Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria, Arthritis Rheum 1996:39, (1): 34–40, 1996 http://onlinelibrary.wiley.com/doi/10.1002/art.1780390105/abstract

  15. Emery P. et al. IL-6 Receptor Inhibition with Tocilizumab Improves Treatment Outcomes in Patients with Rheumatoid Arthritis Refractory to Anti-TNF Biologics: The RADIATE Study. Ann Rheum Dis. 2008;67:1516-1523.

  16. M. L. L. Prevoo, M. A. Van'T Hof, H. H. Kuper, M. A. Van Leeuwen, L. B. A. Van De Putte, P. L. C. M. Van Riel Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum,1995, 38:44–48, January 1995

  17. Jones G et al.: FRI0213 EFFICACY OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD NEVER BEEN EXPOSED TO OR HAD NEVER FAILED METHOTREXATE: ANALYSIS OF UP TO 3 YEARS OF TREATMENT IN A LONG-TERM EXTENSION STUDY, EULAR 2010, Poster 0213, https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=14232

  18. EULAR 2011 - FRI0365 COMPARISON OF TOCILIZUMAB AS MONOTHERAPY OR WITH ADD-ON DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO PREVIOUS TREATMENTS: ACT-SURE RESULTS. J. Sibilia 1,*, W. Graninger 2, A. Östör 3, J. A. Román Ivorra 4, J. Wollenhaupt 5, A. Stancati 6, C. Bernasconi 6, V. Bykerk 7 and ACT-SURE Study Group. Abstract, https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=58163

  19. EULAR 2011- SAT0306: Tocilizumab Treatment in Patients with Rheumatoid Arthritis and Inadequate Response to DMARDs and/or TNF Inhibitors: ACT-SURE Final Results. Vivian P. Bykerk, Jose Álvaro-Gracia, Jose Andres Román Ivorra, Michael T. Nurmohamed, Karel Pavelka, Corrado Bernasconi, Andrea Stancati, Jean Sibilia, Andrew Östör on behalf of ACT-SURE Study Group

  20. EULAR 2011 -OP0020 TOCILIZUMAB (TCZ) PLUS METHOTREXATE (MTX) DOES NOT HAVE SUPERIOR CLINICAL EFFICACY TO TCZ ALONE IN RA PATIENTS WITH INADEQUATE RESPONSE TO MTX: 24-WEEK RESULTS OF THE ACT-RAY STUDY M. Dougados, T. Huizinga, T. Sheeran, P. Tak, P. Conaghan, F. Navarro-Sarabia, A. Hou , C. Bernasconi , K. Kissel
    Abstract
    https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=58181

  21. ACR 2011- 2628 - Double-Blind Study of Tocilizumab Plus Methotrexate Vs Tocilizumab Plus Placebo in Patients with Active Rheumatoid Arthritis Despite Prior Methotrexate: Progression of Structural Damage, Quality of Life, and Physical Function At 24 Weeks. Maxime Dougados et al. Abstract http://acr.confex.com/acr/2011/webprogram/Paper21182.html

  22. J. S. Smolen, F. C. Breedveld , M. H. Schiff, J. R. Kalden , P. Emery , G. Eberl, P. L. van Riel and P. Tugwell
    A simplified disease activity index for rheumatoid arthritis for use in clinical practice
    Rheumatology, 2003, Volume42, Issue2, Pp. 244-257
    Full Text
    rheumatology.oxfordjournals.org/content/42/2/244.full

  23. Daniel Aletaha, Valerie PK Nell, Tanja Stamm, Martin Uffmann, Stephan Pflugbeil, Klaus Machold and Josef S Smolen
    Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
    Arthritis Research & Therapy 2005, 7:R796-R806 
    Full Text
    http://arthritis-research.com/content/7/4/R796,

  24. David T Felson, Josef S Smolen, George Wells et al.: American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials Ann Rheum Dis 2011;70:404-413 doi:10.1136/ard.2011.149765
    Full Text
    http://ard.bmj.com/content/70/3/404.full

  25. Christof Iking-Konert, Martin Aringer, Jürgen Wollenhaupt, Thomas Mosch, Stefan Tuerk, Eugen Feist, Gerd R Burmester Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria
    ARD Online First, published on August 29, 2011 as 10.1136/ard.2011.152678
    http://ard.bmj.com/content/early/2011/08/29/ard.2011.152678.full

  26. EULAR 2011 - AB0600 - C. Iking-Konert, M. Aringer, J. Wollenhaupt, T. Mosch, S. Tuerk, E. Feist, G. Burmester: High remission rates with Tocilizumab in the phase IIIb study TAMARA with the new ACR/EULAR remission criteria,
    b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx

  27. Pressemitteilung 08. Juni 2011: Tocilizumab Mono erzielt hohe Remissionsraten. EULAR zeigt erstmals: Monotherapie vergleichbar wirksam wie eine Kombination mit MTX. 

  28. Daten und Fakten zu RoACTEMRA® Pressekonferenz 22. November 2011: Roche und Chugai in der Rheumatologie: Highlights vom ACR 2011: Medizin nach Maß mit RoACTEMRA®

  29. RoACTEMRA® Studien bei „Roche in Deutschland"

  30. Fachinformation RoActemra® Stand Juli 2011
Copyright © 1997-2024 rheuma-online
rheuma-online Österreich
  
Alle Texte und Beiträge in rheuma-online wurden nach bestem Wissen und Gewissen erstellt. Irrtümer sind jedoch vorbehalten. Alle Angaben sind ohne Gewähr. Jegliche Haftungsansprüche, insbesondere auch solche, die sich aus den Angaben zu Krankheitsbildern, Diagnosen und Therapien ergeben könnten, sind ausgeschlossen.